Clinical Trials · NCT00171886

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Name: Octreotide Efficacy and Safety in First-line Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Octreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 20
Start date: Jul 2002
Locations: 8 sites, Spain
Primary endpoint: To evaluate the ability of Sandostatin® LAR® to decrease GH and IGF-I levels in acromegaly patients with micro- or macroadenomas not previously treated

View Octreotide compound reference